Exploration of virtual candidates for human HMG-CoA reductase inhibitors using pharmacophore modeling and molecular dynamics simulations.
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is a rate-controlling enzyme in the mevalonate pathway which involved in biosynthesis of cholesterol and other isoprenoids. This enzyme catalyzes the conversion of HMG-CoA to mevalonate and is regarded as a drug target to treat hypercholesterole...
Guardado en:
Autores principales: | Minky Son, Ayoung Baek, Sugunadevi Sakkiah, Chanin Park, Shalini John, Keun Woo Lee |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/51fe6cef964249ec9dafd72edd9f96b7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.
por: Richard D Moore, et al.
Publicado: (2011) -
Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol
por: Shi-You Jiang, et al.
Publicado: (2018) -
HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study.
por: Rita Bergqvist, et al.
Publicado: (2021) -
Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors.
por: Melanie Hamalukic, et al.
Publicado: (2011) -
A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease
por: Anna Pierzchlińska, et al.
Publicado: (2021)